AI Clinical Decision Tools Outpace Evidence in Hospital Trials

The deployment problem sponsors didn't budget for

By 2024, 71 percent of U.S. hospitals had integrated predictive AI into their electronic health record systems, according to ONC's Hospital Trends data brief. That adoption rate is moving faster than any investigational new drug application, any protocol amendment cycle, and any regulatory framework currently governing clinical trials. For sponsors running studies at these institutions, the operational implications are immediate: AI decision support tools are already embedded in the clinical workflows generating your source data, and your monitoring plans almost certainly don't account for them.

A recent Nature Medicine analysis highlighted the core tension: evidence generation cannot keep pace with AI adoption in clinical settings. The consequences extend directly to trial integrity, data verification, and regulatory submissions that rely on real-world evidence from AI-augmented environments.

When better process doesn't change outcomes

A randomized study of more than 9,600 patients across 16 primary care clinics in Kenya tested an AI-powered clinical support tool called AI Consult, integrated into the electronic medical record system. Clinicians using the tool showed improved decision-making quality. Short-term patient outcomes, however, did not significantly change, according to Clinical Trial Vanguard.

That gap between modified clinician behavior and unchanged measured endpoints represents an undocumented confounder in trial design. If an AI decision support tool alters how a clinician makes decisions during a study without producing a detectable signal in the primary endpoint, sponsors inherit a variable their protocols did not anticipate. When that tool feeds data into the eClinical stack, source data verification processes face a new challenge monitoring plans weren't designed to interrogate.

Regulatory guidance leaves operational gaps

The FDA published final guidance in December 2024 on predetermined change control plans for AI-enabled device software functions, with an update following in August 2025. The guidance addresses lifecycle management of AI and machine learning-enabled software. What it does not provide is operational specificity on how sponsors or sites should document, flag, or account for AI decision support modifications occurring during an active trial.

Oncology and cardiology sponsors running multi-site trials at academic medical centers face the highest exposure. These institutions have the highest AI adoption rates and the most complex EHR integrations. Aidoc, for instance, received FDA 510(k) clearance for its CARE AI foundation model, a triage solution operating across radiology and clinical decision workflows. When that system runs at a trial site, it influences the clinical judgment generating source data—and monitoring plans typically don't detect its presence.

Decentralized and hybrid trial designs face different risks. When patients interact with AI-assisted telehealth platforms, AI-augmented electronic patient-reported outcome tools, or AI-powered symptom checkers between site visits, the data flowing to electronic data capture systems has already been shaped by an upstream AI layer.

Why it matters

Sponsors who treat AI decision support as a post-approval commercialization issue will discover it embedded in their Phase 3 data packages. Site-level AI adoption doesn't wait for sponsor validation timelines, creating audit trail complications and potential protocol deviations that standard feasibility assessments don't capture. The gap between AI deployment velocity and evidentiary frameworks represents an unbudgeted risk category in trial operations.

The operational response

Clinical operations leaders overseeing multi-site trials at institutions with AI-integrated EHR systems need to add a new section to site feasibility questionnaires. Before randomization begins, sites must document which AI decision support tools are active in clinical workflows, whether those tools interact with data fields feeding the EDC, and what change control processes exist if tools are updated mid-trial.

For sponsors using real-world evidence from AI-augmented environments, study designs must account for AI tool use at data collection sites as a potential effect modifier. Without that accounting, the resulting evidence may not survive methodological scrutiny at the advisory committee level.

The FDA's AI and machine learning-based software as a medical device action plan, first published in January 2021, identified post-market surveillance and adverse event reporting for AI tools as an open action item. Five years later, trial-specific operational guidance has not materialized. The next draft addressing AI in clinical trial operations will carry immediate protocol implications for sponsors running trials at AI-heavy institutions.

These details were first reported by Clinical Trial Vanguard.